MeSH D016781 - cerebral toxoplasmosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Abon Pharmaceuticals | Atovaquone | Atovaquone | 2021-10-25 | |||
| Amneal Pharmaceuticals | Atovaquone | Atovaquone | 2014-03-18 | $15.568 M | Q2/17-Q1/18 | |
| Apotex | Atovaquone | Atovaquone | 2017-10-11 | |||
| BionPharma | Atovaquone | Atovaquone | 2021-03-30 | |||
| Chartwell Pharmaceuticals | Atovaquone | Atovaquone | 2017-04-28 | |||
| Glenmark Pharmaceuticals | Atovaquone | Atovaquone | 2018-11-21 | |||
| Atovaquone, Proguanil | Atovaquone Proguanil | 2011-01-12 | ||||
| GSK | Atovaquone, Proguanil | Malarone | 2000-07-14 | |||
| Atovaquone | Mepron | 1992-11-25 | ||||
| Hetero | Atovaquone | Atovaquone | 2018-10-11 | |||
| Lupin Research | Atovaquone | Atovaquone | 2018-09-11 | |||
| Mylan | Atovaquone, Proguanil | Atovaquone Proguanil | 2014-05-27 |
Clinical Trials
Historical Success Rate
Phase 1
60%3/5
Phase 2
0%0/8
Phase 3
100%1/1
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use